Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shed light on. While Cramer still backed the company, ...

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Shares of Eli Lilly & Co. LLY rallied 2.89% to $798.89 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to 6,358.91 ...

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

ADI shares flashed a Golden Cross pattern on July 1, when the 50-day moving average crossed above the 200-day, a classic ...

Eli Lilly and Company (NYSE: LLY) is one of the best long term low volatility stocks to buy now. In a report released on July ...